(Q41716577)

7 October 2017

title

Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control (English)

1 reference

7 October 2017

0 references

Andrea Calcagno

1

1 reference

7 October 2017

Marco Simiele

2

1 reference

7 October 2017

Maria Chiara Alberione

3

1 reference

7 October 2017

Margherita Bracchi

4

1 reference

7 October 2017

Letizia Marinaro

5

1 reference

7 October 2017

Sara Ecclesia

6

1 reference

7 October 2017

Giovanni Di Perri

7

1 reference

7 October 2017

Antonio D'Avolio

8

1 reference

7 October 2017

Stefano Bonora

9

1 reference

7 October 2017

language of work or name

English

0 references

publication date

3 October 2014

1 reference

Clinical Infectious Diseases

7 October 2017

published in

1 reference

7 October 2017

volume

60

1 reference

7 October 2017

issue

2

1 reference

7 October 2017

page(s)

311-317

1 reference

Current understanding of HIV-associated neurocognitive disorders pathogenesis

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

HIV-associated neurocognitive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Antiretroviral drug treatment of CNS HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Low atazanavir concentrations in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Etravirine in CSF is highly protein bound

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU773

21 January 2018

Identifiers

DOI

10.1093/CID/CIU773

1 reference

release_cjt7zxfrrbhxnovjnopxvguuge

7 October 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cjt7zxfrrbhxnovjnopxvguuge

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference